HBV Citations List: November 2023

Literature Citations

1. Broad-spectrum Activity of Bulevirtide against Clinical Isolates of HDV and Recombinant Pan-genotypic Combinations of HBV/HDV. Mateo, R., S. Xu, A. Shornikov, T. Yazdi, Y. Liu, L. May, B. Han, D. Han, R. Martin, S. Manhas, C. Richards, C. Marceau, T. Aeschbacher, S. Chang, D. Manuilov, J. Hollnberger, S. Urban, T. Asselah, D. Abdurakhmanov, P. Lampertico, E. Maiorova, and H. Mo. Journal of Hepatology Reports, 2023. 5(11): 100893. PMID[37929228]. PMCID[PMC10622701].
[PubMed]. HBV_11_2023.

2. cccDNA-targeted Drug Screen Reveals a Class of Antihistamines as Suppressors of HBV Genome Levels. Ren, E.C., N.Z. Zhuo, Z.Y. Goh, I. Bonne, B. Malleret, and H.L. Ko. Biomolecules, 2023. 13(10): p. 1231-1241. PMID[37892121]. PMCID[PMC10604930].
[PubMed]. HBV_11_2023.

3. Desmethoxycurcumin AIDS IFNα's anti-HBV Activity by Antagonising CRYAB Reduction and Stabilising IFNAR1 Protein. Wei, J., X. Deng, W. Dai, L. Xie, G. Zhang, X. Fan, X. Li, Z. Jin, Q. Xiao, and T. Chen. Journal of Drug Targeting, 2023. 31(9): p. 976-985. PMID[37851377].
[PubMed]. HBV_11_2023.

4. Discovery of Carboxyl Containing Heteroaryldihydropyrimidine Derivatives as Novel HBV Capsid Assembly Modulators with Significantly Improved Metabolic Stability. Zhao, S., Y. Wang, X. Zhang, L. Qiao, S. Wang, Y. Jin, S. Wu, Y. Li, P. Zhan, and X. Liu. Royal Society of Chemistry Medicinal Chemistry, 2023. 14(11): p. 2380-2400. PMID[37974964].
[PubMed]. HBV_11_2023.

Patent Citations

This month, no relevant HBV patents were identified.